Heron's Q3 Sales Up 16%, But Debt Extinguishment Drives Net Loss Spike

TL;DR

**Heron's revenue growth is overshadowed by a massive debt extinguishment loss, making it a risky bet despite product traction.**

AI Summary

Heron Therapeutics, Inc. reported net product sales of $38.213 million for the three months ended September 30, 2025, an increase of 16.4% from $32.810 million in the same period of 2024. For the nine months ended September 30, 2025, net product sales reached $114.316 million, up from $103.504 million in 2024. Despite revenue growth, the company experienced a significant increase in net loss, reporting a net loss of $17.495 million for the three months ended September 30, 2025, compared to a net loss of $4.848 million in the prior year, primarily due to an $11.339 million loss on debt extinguishment. Research and development expenses decreased to $3.470 million for the quarter from $4.465 million in 2024, while sales and marketing expenses rose to $12.942 million from $10.972 million. The company's cash and cash equivalents increased to $43.068 million as of September 30, 2025, from $25.802 million at December 31, 2024, bolstered by $14.208 million in net cash provided by financing activities, including proceeds from common stock and Series A convertible preferred stock sales. Total liabilities decreased to $234.065 million from $266.798 million at year-end 2024, largely due to the extinguishment of $149.700 million in non-current convertible notes payable, offset by new non-current notes payable of $107.487 million. The company's accumulated deficit grew to $1,936.835 million.

Why It Matters

Heron's increased net product sales, particularly with ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, indicate growing market acceptance for its therapeutic innovations, which is crucial for investor confidence in a competitive biotechnology landscape. However, the substantial net loss driven by debt extinguishment costs raises questions about capital structure management and future profitability, potentially impacting employee morale and the company's ability to fund ongoing R&D. For customers, continued commercialization success means access to improved medical care, but financial instability could pose long-term supply risks. The competitive context shows Heron navigating a challenging market where sustained revenue growth must eventually translate into profitability to attract and retain investment.

Risk Assessment

Risk Level: high — The company reported a significant net loss of $17.495 million for the three months ended September 30, 2025, primarily driven by an $11.339 million loss on debt extinguishment. While cash and cash equivalents increased to $43.068 million, the accumulated deficit stands at a substantial $1,936.835 million, indicating a long history of unprofitability and reliance on financing activities, including the issuance of Series A convertible preferred stock and new notes payable.

Analyst Insight

Investors should exercise caution and closely monitor Heron's path to profitability, specifically focusing on how new debt is managed and if revenue growth can consistently outpace operating expenses and financing costs. Consider waiting for a clear trend of reduced net losses and positive operating cash flow before making a significant investment.

Financial Highlights

debt To Equity

15.72

revenue

$38.213M

operating Margin

-10.7%

total Assets

$248.950M

total Debt

$234.065M

net Income

-$17.495M

eps

-$0.10

gross Margin

68.8%

cash Position

$43.068M

revenue Growth

+16.4%

Revenue Breakdown

Key Numbers

• $38.213M — Net Product Sales (Q3 2025) (Increased 16.4% from $32.810M in Q3 2024)
• $114.316M — Net Product Sales (9M 2025) (Increased from $103.504M in 9M 2024)
• $17.495M — Net Loss (Q3 2025) (Significantly higher than $4.848M net loss in Q3 2024)
• $11.339M — Loss on Debt Extinguishment (Primary driver of increased net loss in Q3 2025)
• $43.068M — Cash and Cash Equivalents (Sep 30, 2025) (Increased from $25.802M at Dec 31, 2024)
• $107.487M — Non-current notes payable, net (Sep 30, 2025) (Increased from $25.026M at Dec 31, 2024)
• $32.176M — Non-current convertible notes payable, net (Sep 30, 2025) (Decreased from $149.700M at Dec 31, 2024 due to extinguishment)
• $1,936.835M — Accumulated Deficit (Sep 30, 2025) (Increased from $1,919.594M at Dec 31, 2024)
• $14.208M — Net Cash Provided by Financing Activities (9M 2025) (Significant increase from $0.517M in 9M 2024)
• 183,362,522 — Common Shares Outstanding (Oct 30, 2025) (Increased from 152,128,000 at Dec 31, 2024, indicating dilution)

Key Players & Entities

• HERON THERAPEUTICS, INC. (company) — Registrant
• ZYNRELEF (company) — Product
• APONVIE (company) — Product
• CINVANTI (company) — Product
• SUSTOL (company) — Product
• CrossLink Network, LLC (company) — Co-promotion agreement partner
• U.S. Food and Drug Administration (regulator) — Regulatory body
• $38.213 million (dollar_amount) — Net product sales for Q3 2025
• $17.495 million (dollar_amount) — Net loss for Q3 2025
• $11.339 million (dollar_amount) — Loss on debt extinguishment for Q3 2025

FAQ

Risk Factors

• Debt Extinguishment and Refinancing [high — financial]: The company incurred a significant $11.339 million loss on debt extinguishment in Q3 2025. While total liabilities decreased due to the extinguishment of $149.700 million in convertible notes, new non-current notes payable increased to $107.487 million, indicating ongoing reliance on debt financing.
• Growing Accumulated Deficit [high — financial]: The accumulated deficit increased to $1,936.835 million as of September 30, 2025. This trend, coupled with a net loss of $17.495 million in Q3 2025, highlights the company's ongoing struggle to achieve profitability.
• Dilution from Equity Issuances [medium — financial]: The number of common shares outstanding increased from 152,128,000 at December 31, 2024, to 183,362,522 as of October 30, 2025. This dilution, partly driven by financing activities including stock sales, could negatively impact existing shareholders.
• Increased Sales and Marketing Expenses [medium — operational]: Sales and marketing expenses rose to $12.942 million in Q3 2025 from $10.972 million in Q3 2024. While this may support revenue growth, it also puts pressure on profitability.
• Inventory Growth [medium — operational]: Inventory increased to $70.025 million as of September 30, 2025, from $53.160 million at December 31, 2024. This could indicate potential challenges in sales velocity or production planning.
• Dependence on Financing Activities [medium — financial]: The company's cash position improved significantly to $43.068 million, largely due to $14.208 million in net cash provided by financing activities. This reliance on external financing for liquidity suggests a need for sustainable operational cash flow generation.

Industry Context

Heron Therapeutics operates in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies. The sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Competition is intense, with companies vying for market share in therapeutic areas like oncology and critical care.

Regulatory Implications

As a biopharmaceutical company, Heron is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing practices is critical. Any failure to adhere to these regulations could result in significant penalties, product recalls, or delays in drug approvals.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net product sales of $38.213M, a 16.4% increase year-over-year, but a net loss of $17.495M, significantly impacted by a $11.339M loss on debt extinguishment.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents increased to $43.068M. Total liabilities decreased to $234.065M due to debt extinguishment, but non-current notes payable increased.
• 2024-12-31: End of Fiscal Year 2024 — Reported cash and cash equivalents of $25.802M and total liabilities of $266.798M, with $149.700M in non-current convertible notes payable.

Glossary

Loss on debt extinguishment

A non-cash charge recognized when a company repays or retires debt before its scheduled maturity date, often involving a premium payment or unamortized issuance costs. (This was the primary driver of the significant increase in net loss for Q3 2025, impacting profitability.)

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (The growing accumulated deficit to $1,936.835 million indicates the company has historically operated at a loss and has not yet achieved sustained profitability.)

Non-current convertible notes payable

Long-term debt instruments that can be converted into a predetermined amount of the issuer's equity. The 'net' indicates any unamortized discount or premium. (A significant portion of this debt ($149.700M) was extinguished, impacting the company's balance sheet and P&L.)

Additional paid-in capital

The amount of money a company receives from selling stock above its par value. (This account increased significantly, reflecting proceeds from stock sales used to bolster cash reserves.)

Right-of-use lease assets

Assets recognized under lease accounting standards representing the lessee's right to use an underlying asset for the lease term. (These assets decreased, suggesting a reduction in leased property or equipment.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Heron Therapeutics shows positive revenue growth, with net product sales up 16.4% in Q3 2025 and 9M 2025. However, profitability has significantly deteriorated, with net loss widening substantially in Q3 2025, primarily due to a large loss on debt extinguishment. While cash reserves have increased due to financing activities, R&D expenses have decreased, and sales and marketing expenses have risen, indicating a shift in operational focus and cost structure.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M

Filing Documents

• hrtx-20250930.htm (10-Q) — 2313KB
• hrtx-ex10_1.htm (EX-10.1) — 237KB
• hrtx-ex10_7.htm (EX-10.7) — 1015KB
• hrtx-ex10_8.htm (EX-10.8) — 23KB
• hrtx-ex31_1.htm (EX-31.1) — 17KB
• hrtx-ex31_2.htm (EX-31.2) — 17KB
• hrtx-ex32_1.htm (EX-32.1) — 19KB
• 0001193125-25-263618.txt ( ) — 10176KB
• hrtx-20250930.xsd (EX-101.SCH) — 973KB
• hrtx-20250930_htm.xml (XML) — 1676KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 32 ITEM 4.

Controls and Procedures

Controls and Procedures 32 PART II. OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 33 ITEM 1A.

Risk Factors

Risk Factors 35 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 ITEM 3. Defaults upon Senior Securities 37 ITEM 4. Mine Safety Disclosures 37 ITEM 5. Other Information 37 ITEM 6. Exhibits 38

SIGNATURES

SIGNATURES 40 In this Quarterly Report on Form 10-Q, all references to "Heron," the "Company," "we," "us," "our" and similar terms refer to Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V. Heron Therapeutics , the Heron logo, ZYNRELEF , APONVIE , CINVANTI , SUSTOL , and Biochronomer are our trademarks, which are protected under applicable intellectual property laws and are the property of Heron. All other trademarks appearing or incorporated by reference into this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks referred to in this Quarterly Report on Form 10-Q may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks. We do not intend our use or display of other parties' trademarks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. 1

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by the use of the words "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "might," "project," "should," "will," "would," and other expressions that predict or indicate future events and trends and which do not relate to historical matters. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business and commercialization strategy, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, addressable patient population, research and development expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from our anticipated future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking statements include, but are not limited to, statements including

Forward-looking statements include, but are not limited to, statements including: our ability to successfully commercialize, market and achieve market acceptance of ZYNRELEF (bupivacaine and meloxicam) extended-release solution ("ZYNRELEF"), APONVIE (aprepitant) injectable emulsion ("APONVIE"), CINVANTI (aprepitant) injectable emulsion ("CINVANTI"), and SUSTOL (granisetron) extended-release injection ("SUSTOL" and together with ZYNRELEF, APONVIE and CINVANTI, our "Products") in the United States ("U.S."), and our positioning relative to products that now or in the future compete with our Products or product candidates; our estimates regarding the potential market opportunities for our Products and our product candidates, if approved, and our ability to capture the potential additional market opportunity from the expanded ZYNRELEF label approved in the U.S.; our ability to establish and maintain successful commercial arrangements, including our co-promotion agreement with CrossLink Network, LLC ("CrossLink Network"); the realization of anticipated benefits from our co-promotion agreement with CrossLink Network; the timing and outcome of our pending patent litigations; whether we are required to write-off any additional inventory in the future; our ability to establish satisfactory pricing and obtain adequate reimbursement from government and third-party payors of our Products and product candidates that receive regulatory approvals; whether clinical trials of our Products and product candidates are indicative of the results in future clinical trials; our ability to successfully launch our ZYNRELEF Vial Access Needle ("VAN") in the U.S.; our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials, and our ability to submit for and obtain regulatory approval for product candidates in our anticipated timing, or at all; the clinical utility of our Products and product candidates and their potential

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

CONDENSED CONSOL IDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOL IDATED FINANCIAL STATEMENTS HERON THERAPEUTICS, INC. Condensed Consolida ted Balance Sheets (In thousands) September 30, 2025 December 31, 2024 (Unaudited) (See Note 2) ASSETS Current assets: Cash and cash equivalents $ 43,068 $ 25,802 Short-term investments 12,419 33,481 Accounts receivable, net 81,047 78,881 Inventory, net 70,025 53,160 Prepaid expenses and other current assets 22,841 17,690 Total current assets 229,400 209,014 Property and equipment, net 12,960 14,863 Right-of-use lease assets 708 2,787 Other assets 5,882 6,483 Total assets $ 248,950 $ 233,147 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 12,017 $ 11,709 Accrued clinical and manufacturing liabilities 19,663 25,402 Accrued payroll and employee liabilities 8,748 9,554 Other accrued liabilities 48,500 41,755 Current lease liabilities 780 3,037 Total current liabilities 89,708 91,457 Non-current notes payable, net 107,487 25,026 Non-current convertible notes payable, net 32,176 149,700 Other non-current liabilities 4,694 615 Total liabilities 234,065 266,798 Stockholders' equity (deficit): Common stock 1,833 1,521 Series A convertible preferred stock 7,862 — Additional paid-in capital 1,942,025 1,884,409 Accumulated other comprehensive loss — 13 Accumulated deficit ( 1,936,835 ) ( 1,919,594 ) Total stockholders' equity (deficit) 14,885 ( 33,651 ) Total liabilities and stockholders' equity (deficit) $ 248,950 $ 233,147 See accompanying notes. 5 HERON THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues: Net product sales $